Previous Close | 0.5302 |
Open | 0.5780 |
Bid | 0.5300 x 1000 |
Ask | 0.5287 x 1000 |
Day's Range | 0.5120 - 0.5780 |
52 Week Range | 0.2620 - 16.5000 |
Volume | |
Avg. Volume | 344,372 |
Market Cap | 5.119M |
Beta (5Y Monthly) | 1.22 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -4.7000 |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 55.00 |
Subscribe to Yahoo Finance Plus to view Fair Value for BSGM
Westport, CT, Feb. 20, 2024 (GLOBE NEWSWIRE) -- -- BioSig Technologies, Inc. (NASDAQ: BSGM) ("BioSig" or the "Company"), a medical technology company, today announced that it has terminated a significant number of its employees and expects to substantially reduce business operations. About BioSig Technologies, Inc.BioSig Technologies is a medical technology company. The Company's product, the PURE EP™ Platform, an FDA 510(k) cleared non-invasive class II device, provides superior, real-time sign
Company sees clinical adoption and usage of its novel Near Field Tracking algorithm, proven to reduce ablation time by approximately 66%.Westport, CT, Feb. 06, 2024 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company committed to delivering unprecedented accuracy and precision to intracardiac signal visualization, today announced that physicians have completed over 100 cases with the Near Field Tracking (“NFT”) algorithm, an inno
Common Stock Will Begin Trading on Split-Adjusted Basis on February 2, 2024Westport, CT, Jan. 31, 2024 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) ("BioSig" or the "Company"), a medical technology company committed to delivering unprecedented accuracy and precision to intracardiac signal visualization, today announced that it intends to effect a reverse stock split of its common stock at a ratio of 1 post-split share for every 10 pre-split shares. The reverse stock split will be